Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Collaborative innovation in drug discovery : strategies for public and private partnerships / / edited by Dr. Rathnam Chaguturu ; Nobel Laureate Ferid Murad, foreword ; contributors Khusru Asadullah [and sixty four others]
| Collaborative innovation in drug discovery : strategies for public and private partnerships / / edited by Dr. Rathnam Chaguturu ; Nobel Laureate Ferid Murad, foreword ; contributors Khusru Asadullah [and sixty four others] |
| Pubbl/distr/stampa | Hoboken, New Jersey : , : Wiley, , 2014 |
| Descrizione fisica | 1 online resource (760 p.) |
| Disciplina | 615.1/9 |
| Collana | Wiley Series on Technologies for the Pharmaceutical Industry |
| Soggetto topico |
Drug Discovery
Public-Private Sector Partnerships Drug development Public-private sector cooperation |
| ISBN |
1-118-77816-2
1-118-77815-4 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Cover; Title page; Copyright page; Dedication; Collaborative Drug Discovery Ethos; Contents; Foreword; Preface; About the Book; About the Editor; Contributors; Part I: Perspectives on Collaborative Innovation; 1: Productive Relationships in Research and Development between Government, Industry, and Universities; Universities, Government, and Industry: Historical Beginnings in Prussia; Refinement and Broad Adoption: the United States; Land Grants; Investments in Research; Intellectual Property; Impact on U.S. Economy; General Principles for Success; Governments; Universities; Industry
2: Divided We FallChallenges; Collaboration Models; Examples of Successful Biomedical Collaborations; Biomarkers Consortium; Predictive Safety Testing Consortium; SNP and SAEC Consortia; Principles of Collaboration; Governance, Administration, and Autonomy; Human Factors; Conclusion; References; 3: Innovation: Open Source and Nonprofit Models in Drug Discovery; Why Do People Innovate?; How Do We Encourage Innovation?; Why Is Innovation Important?; Warnings Regarding Innovation in Drug Discovery; Open Source Models; Nonprofit Models; Recommendations; References 4: The Changing Face of Innovation in Drug DiscoveryIntroduction; Core Objectives of the Drug Discovery Process; Major Innovations in Technology Have Advanced Drug Discovery; Target Identification and Target Validation; Hit Identification: The First Stage in Drug Hunting; Lead Optimization: A Field to Which Companies Must Commit Major Amounts of Human and Financial Resources; Preclinical Assessment: Select the First-in-Class and/or Best-in-Class Drug Candidate for Clinical Development; An Important Trend: Academic and Pharmaceutical Organizations Are Collaborating in Support of Drug Discovery Future Perspectives: Where Is Innovation Leading?References; 5: Current Trends in Collaborative Drug Discovery and Strategies to De-Risk Precompetitive Initiatives; Pharmaceutical Industry's Perspective; Academia's Perspective; Open (Collaborative) Innovation: A New Business Model; Drug Discovery through Collaborations; Drug Discovery through Consortia; Drug Discovery through Repurposing Strategies; Probe Discovery in Public Domain; Effective Management of Academia-Pharma Collaborations; Concluding Remarks; References 6: A Perspective on the Evolution of Collaborative Drug Discovery and Future ChallengesEvolution of Collaborative Drug Discovery; Challenges for Collaborative Drug Discovery; Conclusion; References; Part II: Governmental Initiatives Accelerate Precompetitive Collaboration; 7: The Value of University-Industry Partnerships; Guiding Principles for University-Industry Collaborations; The Johnson Continuum; Role of Cocreation: Companies, Government, and Universities; Maryland Industrial Partnerships (MIPS) Program; Funding for Collaborations with Academia New Initiatives to Transform University-Industry Collaborations |
| Record Nr. | UNINA-9910139118703321 |
| Hoboken, New Jersey : , : Wiley, , 2014 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Collaborative innovation in drug discovery : strategies for public and private partnerships / / edited by Dr. Rathnam Chaguturu ; Nobel Laureate Ferid Murad, foreword ; contributors Khusru Asadullah [and sixty four others]
| Collaborative innovation in drug discovery : strategies for public and private partnerships / / edited by Dr. Rathnam Chaguturu ; Nobel Laureate Ferid Murad, foreword ; contributors Khusru Asadullah [and sixty four others] |
| Pubbl/distr/stampa | Hoboken, New Jersey : , : Wiley, , 2014 |
| Descrizione fisica | 1 online resource (760 p.) |
| Disciplina | 615.1/9 |
| Collana | Wiley Series on Technologies for the Pharmaceutical Industry |
| Soggetto topico |
Drug Discovery
Public-Private Sector Partnerships Drug development Public-private sector cooperation |
| ISBN |
1-118-77816-2
1-118-77815-4 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Cover; Title page; Copyright page; Dedication; Collaborative Drug Discovery Ethos; Contents; Foreword; Preface; About the Book; About the Editor; Contributors; Part I: Perspectives on Collaborative Innovation; 1: Productive Relationships in Research and Development between Government, Industry, and Universities; Universities, Government, and Industry: Historical Beginnings in Prussia; Refinement and Broad Adoption: the United States; Land Grants; Investments in Research; Intellectual Property; Impact on U.S. Economy; General Principles for Success; Governments; Universities; Industry
2: Divided We FallChallenges; Collaboration Models; Examples of Successful Biomedical Collaborations; Biomarkers Consortium; Predictive Safety Testing Consortium; SNP and SAEC Consortia; Principles of Collaboration; Governance, Administration, and Autonomy; Human Factors; Conclusion; References; 3: Innovation: Open Source and Nonprofit Models in Drug Discovery; Why Do People Innovate?; How Do We Encourage Innovation?; Why Is Innovation Important?; Warnings Regarding Innovation in Drug Discovery; Open Source Models; Nonprofit Models; Recommendations; References 4: The Changing Face of Innovation in Drug DiscoveryIntroduction; Core Objectives of the Drug Discovery Process; Major Innovations in Technology Have Advanced Drug Discovery; Target Identification and Target Validation; Hit Identification: The First Stage in Drug Hunting; Lead Optimization: A Field to Which Companies Must Commit Major Amounts of Human and Financial Resources; Preclinical Assessment: Select the First-in-Class and/or Best-in-Class Drug Candidate for Clinical Development; An Important Trend: Academic and Pharmaceutical Organizations Are Collaborating in Support of Drug Discovery Future Perspectives: Where Is Innovation Leading?References; 5: Current Trends in Collaborative Drug Discovery and Strategies to De-Risk Precompetitive Initiatives; Pharmaceutical Industry's Perspective; Academia's Perspective; Open (Collaborative) Innovation: A New Business Model; Drug Discovery through Collaborations; Drug Discovery through Consortia; Drug Discovery through Repurposing Strategies; Probe Discovery in Public Domain; Effective Management of Academia-Pharma Collaborations; Concluding Remarks; References 6: A Perspective on the Evolution of Collaborative Drug Discovery and Future ChallengesEvolution of Collaborative Drug Discovery; Challenges for Collaborative Drug Discovery; Conclusion; References; Part II: Governmental Initiatives Accelerate Precompetitive Collaboration; 7: The Value of University-Industry Partnerships; Guiding Principles for University-Industry Collaborations; The Johnson Continuum; Role of Cocreation: Companies, Government, and Universities; Maryland Industrial Partnerships (MIPS) Program; Funding for Collaborations with Academia New Initiatives to Transform University-Industry Collaborations |
| Record Nr. | UNINA-9910815052503321 |
| Hoboken, New Jersey : , : Wiley, , 2014 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Compound Solutions [[electronic resource] ] : Pharmaceutical Alternatives for Global Health / / Susan Craddock
| Compound Solutions [[electronic resource] ] : Pharmaceutical Alternatives for Global Health / / Susan Craddock |
| Autore | Craddock Susan |
| Pubbl/distr/stampa | Minneapolis, Minnesota ; ; London, [England] : , : University of Minnesota Press, , 2017 |
| Descrizione fisica | 1 online resource (183 pages) : illustrations |
| Disciplina | 615.19 |
| Soggetto topico |
Public-Private Sector Partnerships
Tuberculosis - drug therapy Drug Discovery Global Health Antitubercular Agents Technology, Pharmaceutical |
| Soggetto genere / forma | Electronic books. |
| ISBN | 1-4529-5377-5 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | The possibilities and parameters of drug and vaccine partnerships -- Scientific collaboration, innovation, and contradiction -- The contingent ethics of tuberculosis clinical trials -- Conclusion : tuberculosis and the future of humanitarian pharmaceutical production. |
| Record Nr. | UNINA-9910158624303321 |
Craddock Susan
|
||
| Minneapolis, Minnesota ; ; London, [England] : , : University of Minnesota Press, , 2017 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
